Insider Selling: Aura Biosciences, Inc. (NASDAQ:AURA) SVP Sells 1,404 Shares of Stock

Aura Biosciences, Inc. (NASDAQ:AURAGet Free Report) SVP Amy Elazzouzi sold 1,404 shares of the stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $7.75, for a total transaction of $10,881.00. Following the completion of the sale, the senior vice president now owns 82,278 shares of the company’s stock, valued at approximately $637,654.50. The trade was a 1.68 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Amy Elazzouzi also recently made the following trade(s):

  • On Tuesday, January 21st, Amy Elazzouzi sold 1,001 shares of Aura Biosciences stock. The shares were sold at an average price of $7.67, for a total transaction of $7,677.67.

Aura Biosciences Stock Down 3.8 %

Shares of AURA stock opened at $7.65 on Wednesday. Aura Biosciences, Inc. has a 52 week low of $6.63 and a 52 week high of $12.38. The stock has a market capitalization of $382.12 million, a PE ratio of -4.42 and a beta of 0.29. The firm has a 50 day moving average of $8.07 and a two-hundred day moving average of $8.76.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the stock. Lifesci Capital upgraded shares of Aura Biosciences to a “strong-buy” rating in a report on Friday, January 31st. HC Wainwright restated a “buy” rating and set a $22.00 price target on shares of Aura Biosciences in a report on Thursday, November 14th. Five equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, Aura Biosciences currently has a consensus rating of “Buy” and a consensus target price of $23.00.

Check Out Our Latest Research Report on Aura Biosciences

Hedge Funds Weigh In On Aura Biosciences

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. BNP Paribas Financial Markets purchased a new position in Aura Biosciences in the 4th quarter valued at approximately $50,000. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Aura Biosciences during the 4th quarter worth $87,000. ProShare Advisors LLC purchased a new stake in shares of Aura Biosciences during the 4th quarter worth $127,000. Harvest Investment Services LLC purchased a new stake in shares of Aura Biosciences during the 4th quarter worth $133,000. Finally, AlphaQuest LLC purchased a new stake in shares of Aura Biosciences during the 4th quarter worth $136,000. Hedge funds and other institutional investors own 96.75% of the company’s stock.

About Aura Biosciences

(Get Free Report)

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.

See Also

Insider Buying and Selling by Quarter for Aura Biosciences (NASDAQ:AURA)

Receive News & Ratings for Aura Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aura Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.